NIKKEI 225
38,229.11 +155.13 (+0.41%) HANG SENG
18,931.62 +393.81 (+2.12%) CRUDE OIL
79.89 +0.63 (+0.79%) GOLD FUTURES
2,368.80 +28.50 (+1.22%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,113.73 +893.60 (+1.82%)
Iovance Biotherapeutics, Inc. (IOVA)
After hours:
| Previous close | 13.39 |
| Open | 13.38 |
| Bid | 11.48 x 100 |
| Ask | 15.42 x 100 |
| Day's range | 13.04 - 13.59 |
| 52-week range | 3.21 - 18.33 |
| Volume | |
| Avg. volume | 8,805,635 |
| Market cap | 3.764B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.00 |
GlobeNewswireIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi Regulatory Submissions on Track in the European Union (EU), United Kingdom (UK), and Canada in 2024 SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a com
ZacksWatch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
ZacksIovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
